Efficacy and tolerability of alirocumab in Austrian clinical practice – results of the non-interventional PEARL-AT study

R. Leitner, Deborah; Toplak, Hermann; Kedenko, Ludmilla; Steinmaurer, Thomas; Gräff, Verena; Metzner, Thomas; Schwaiger, Elisabeth; Prager, Rudolf

doi:10.1080/03007995.2020.1786678

Public

Efficacy and tolerability of alirocumab in Austrian clinical practice – results of the non-interventional PEARL-AT study

Published in Current Medical Research and Opinion • Jun 22, 2020

Authors:

Deborah R. Leitner

Hermann Toplak

Ludmilla Kedenko

Abstract

OBJECTIVE: Proprotein convertase subtilisin/kexin type 9 inhibition can be an effective treatment in patients with primary hypercholesterolemia, particularly in cases with concomitant coronary heart disease, peripheral artery occlusive disease or cerebrovascular occlusive disease for secondary preve...

Subject

Medicine

Tolerability

Alirocumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!